De-implementing Inhaled Corticosteroids to Improve Quality and Safety for Patients with mild-to-moderate COPD: Mixed-methods Findings of Primary-care Providers’ Perspectives

Dec 15,2017 | Consortium_staff Webinars

VA Health Services Research and Development Cyberseminars 
Date(s): December 7, 2017 12:00pm ET 
Presented by: Christian Helfrich, Krystel Stryczek

Inhaled corticosteroids (ICS) are widely used to treat mild to moderate chronic obstructive pulmonary disease (COPD) despite an increased risk of pneumonia and the availability of safer alternatives. As part of a quality improvement initiative to discontinue inappropriate ICS therapy, the presenters used interviews and surveys to explore primary care providers’ experiences prescribing ICS for patients with mild to moderate COPD. In this Cyberseminar, the presenters discussed findings about the role of multiple prescribing providers and awareness of practice guidelines, and implications for other efforts to de-prescribe ineffective or harmful therapies.

The intended audience for this cyberseminar is researchers studying de-implementation of ineffective and harmful practices and clinicians and administrators interested in patient safety.

Archived audio and transcript is available at the Cyberseminars Past Sessions Archive.